Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18766260 | 0.94 | ALDH1A1 (0.53) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL3010038 | 0.94 | ALDH1A1 (0.53) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL3010040 | 0.94 | ALDH1A1 (0.53) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL29563014 | 0.94 | ALDH1A1 (0.53) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL3402343 | 0.94 | ALDH1A1 (0.53) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL28092553 | 0.92 | ALDH1A1 (0.51) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL28092554 | 0.92 | ALDH1A1 (0.51) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL16698433 | 0.91 | ALDH1A1 (0.50) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL16698435 | 0.91 | ALDH1A1 (0.50) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL29528227 | 0.88 | ACE (0.50) | ALDH1A1LAP3MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2026-01-08 | — | — | US | claimed |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | BIO THERA SOLUTIONS LTD (CN) | 2025-12-18 | — | — | US | claimed |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-21 | — | — | US | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| US-20250249114-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-07 | — | — | US | claimed |
| EP-4556027-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2025-05-21 | — | — | EP | claimed |
| EP-4545099-A1 | METHOD FOR TREATING SOLID TUMOR | Bio-Thera Solutions, Ltd. (CN) | 2025-04-30 | — | — | EP | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| WO-2022253284-A1 | DRUG CONJUGATE AND USE THEREOF | 百奥泰生物制药股份有限公司 | 2022-12-08 | — | — | WO | claimed |
| US-20220372152-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. | 2022-11-24 | — | — | US | claimed |
| WO-2022192134-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | IMMUNOGEN, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| CN-106604927-B | Cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2022-08-09 | — | — | CN | claimed |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2022-05-17 | — | — | US | claimed |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN SWITZERLAND GMBH (CH) | 2022-04-14 | — | — | US | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | NECTIN4, VSIG8, IGSF11 | ALDH1A1 1734/4885LAP3 3241/4885MEN1 1693/4885 |
| US-20250249114-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | ERBB2, EGFR, ERBB3 | ALDH1A1 3196/4885LAP3 341/4885MEN1 2613/4885 |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | ALDH1A1 1927/4885LAP3 960/4885MEN1 786/4885 |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | NECTIN4, CD22, NGFR | ALDH1A1 2339/4885LAP3 1173/4885MEN1 1105/4885 |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VIP, AREG, MIF | ALDH1A1 1927/4885LAP3 960/4885MEN1 786/4885 |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | ALDH1A1 1615/4885LAP3 4651/4885MEN1 1710/4885 |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CNTN1, EPCAM, SLC22A8 | ALDH1A1 728/4885LAP3 1437/4885MEN1 2360/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | ALDH1A1 2585/4885LAP3 1496/4885MEN1 924/4885 |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | TPM4, TPM3, TPST2 | ALDH1A1 1289/4885LAP3 2203/4885MEN1 2103/4885 |
| US-20220372152-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IL23R, CD22, IL2RA | ALDH1A1 1167/4885LAP3 51/4885MEN1 3404/4885 |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | ALDH1A1 1167/4885LAP3 51/4885MEN1 3404/4885 |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | FCGR2A, FCGR1A, FCGR3B | ALDH1A1 378/4885LAP3 1290/4885MEN1 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.